Colon cancer is a leading cause of morbidity and mortality in Western countries. Basic fibroblast growth factor (bFGF) was up-regulated in patients with colon cancer and was considered as a potential therapeutic target. In this study, we first demonstrated that a novel bFGF-binding peptide (named P7) inhibited proliferation of several colon cancer cell lines including HT-29, LoVo, and Caco2 cells stimulated by bFGF. Further investigations with HT-29 cells indicated that P7 arrested the cell cycle at the G0/G1 phase of bFGF-stimulated cells, reduced the levels of phospho-Erk1/Erk2 induced by bFGF, and caused significant changes in the expression of proteins related to proliferation, cell cycle, and cancer. Our results suggested that the bFGF-binding peptide has a potential antitumor effect on colon cancer. © 2010 Japanese Cancer Association.
CITATION STYLE
Wang, C., Lin, S., Nie, Y., Jia, X., Wang, J., Xiao, J., … Wu, X. (2010). Mechanism of antitumor effect of a novel bFGF binding peptide on human colon cancer cells. Cancer Science, 101(5), 1212–1218. https://doi.org/10.1111/j.1349-7006.2010.01501.x
Mendeley helps you to discover research relevant for your work.